CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Forward Pharma A/S (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Forward Pharma A/S (ADR)
Strandvejen 125
Phone: +45 33444244p:+45 33444244 Hellerup, 2900  Denmark Fax: +45 33444244f:+45 33444244
This company is no longer actively traded on any major stock exchange.
Business Summary
Forward Pharma A/S is a Denmark-based biopharmaceutical company, that commenced development in 2005 of a formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer Claus B.Svendsen 44 1/1/2021 3/1/2017
Vice President - Finance, Controller, FP USA ThomasCarbone 64 8/1/2014 8/1/2014
Chairman of the Board FlorianSchonharting 53 7/1/2005 7/1/2005
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Forward Pharma FA ApS
Forward Pharma GmbH
Forward Pharma Operations ApS
Forward Pharma USA, LLC

General Information
Number of Employees: 4 (As of 12/31/2021)
Outstanding Shares: 343,925 (As of 6/8/2023)
Shareholders: 26
Stock Exchange: OTC
Fax Number: +45 33444244
Email Address: info@forward-pharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024